Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022
12 sept. 2022 03h00 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022
10 sept. 2022 09h15 HE
|
ImCheck Therapeutics SAS
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more checkpoint-inhibitor regimen, across a range of ICT01 doses in...
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
10 sept. 2022 04h00 HE
|
Elevar Therapeutics
Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1 inhibitor...
Immatics präsentiert umfangreiche präklinische Daten für bispezifischen TCR-Kandidaten IMA402 gegen die Zielstruktur PRAME auf der Jahrestagung der Europäischen Gesellschaft für Medizinische Onkologie (ESMO)
10 sept. 2022 03h06 HE
|
Immatics N.V.
IMA402 ist ein bispezifischer TCR-Kandidat (T cell engaging receptor, TCER®) der nächsten Generation mit verlängerter Halbwertszeit, der gegen ein HLA-A*02:01-präsentiertes Peptid des Antigens PRAME...
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
10 sept. 2022 03h06 HE
|
https://immatics.com/
TCER® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME In preclinical studies, IMA402 demonstrated enhanced...
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
10 sept. 2022 03h00 HE
|
Anaveon
- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...
Florida Cancer Specialists & Research Institute Physicians Present Cancer Care Advancements at Global Oncology Gathering
08 sept. 2022 12h30 HE
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is among the latest cutting-edge developments and findings...
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
07 sept. 2022 18h05 HE
|
Elevar Therapeutics
Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1...
NKGen Biotech To Present SNK01 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2022
06 sept. 2022 14h37 HE
|
NKGen Biotech
SANTA ANA, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
Predicine Expands to Europe with the recently launched CE-Marked cfDNA Assay PredicineCARE™ for Genomic Profiling in Blood and Urine
09 août 2022 08h00 HE
|
Predicine
SILICON VALLEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine....